CVRX Stock Gains on Unveiling of Barostim's Positive Study Data [Yahoo! Finance]
CVRx, Inc. (CVRX)
Company Research
Source: Yahoo! Finance
The data was published in the Journal of the American College of Cardiology: Heart Failure. The publication builds on the data from the BeAT-HF trial published in 2024 in the European Journal of Heart Failure, demonstrating the long-term sustained symptomatic benefits of Barostim in heart failure patients with reduced ejection fraction. Shares of CVRX gained 3.2% on Friday on the announcement of the publication of the new data. More on CVRX's New Study Data Barostim technology stimulates baroreceptors located in the carotid artery wall with electrical pulses. The body's baroreflex is triggered by the pulses, which cause the heart to respond. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the United States. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. Barostim was used in conjunction with guideline-directed medical therapy (GDMT) by the study par
Show less
Read more
Impact Snapshot
Event Time:
CVRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CVRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CVRX alerts
High impacting CVRx, Inc. news events
Weekly update
A roundup of the hottest topics
CVRX
News
- CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim [Yahoo! Finance]Yahoo! Finance
- CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with BarostimGlobeNewswire
- CVRx Inc (CVRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Rising Expenses [Yahoo! Finance]Yahoo! Finance
- CVRx, Inc. (NASDAQ: CVRX) had its price target raised by analysts at Piper Sandler from $16.00 to $20.00. They now have an "overweight" rating on the stock.MarketBeat
- CVRx, Inc. (NASDAQ: CVRX) had its price target raised by analysts at Canaccord Genuity Group Inc. from $22.00 to $23.00. They now have a "buy" rating on the stock.MarketBeat
CVRX
Earnings
- 2/4/25 - Miss
CVRX
Sec Filings
- 2/14/25 - Form 3
- 2/6/25 - Form SCHEDULE
- 2/6/25 - Form SCHEDULE
- CVRX's page on the SEC website